Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bone BiologicsBBLG -1.82%30 Equity-to-Asset is 0.89 as of Jun. 2026. GuruFocus rates BBLG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Bone Biologics ranks better than 80.69% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bone Biologics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $3.93 Mil. Bone Biologics's Total Assets for the quarter that ended in Jun. 2026 was $4.44 Mil.
The historical rank and industry rank for Bone Biologics's Equity-to-Asset or its related term are showing as below:
BBLG'
s Equity-to-Asset Range Over the Past 10 Years
Min: -12845 Med: -3.05 Max: 0.99
Current: 0.89
During the past 12 years, the highest Equity to Asset Ratio of Bone Biologics was 0.99. The lowest was -12845.00. And the median was -3.05.
BBLG's Equity-to-Asset is ranked better than 80.69% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs BBLG: 0.89
Bone Biologics (NAS:BBLG) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Bone Biologics Equity-to-Asset Related Terms
Bone Biologics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Bone Biologics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBLG vs SCNI, ATXI, PTIX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Bone Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bone Biologics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bone Biologics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bone Biologics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bone Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bone Biologics (BBLG) has a Equity-to-Asset of 0.89 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bone Biologics and its competitors. According to the industry distribution chart, Bone Biologics ranks #273 out of 1414 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Bone Biologics' Equity-to-Asset too high?
Bone Biologics' current Equity-to-Asset is 0.89. The Biotechnology industry median Equity-to-Asset is 0.68. Bone Biologics' value of 0.89 is 30.9% above this industry median. Based on the distribution chart, Bone Biologics ranks #273 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bone Biologics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' Equity-to-Asset compare to SCNI and ATXI?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #273 out of 1414 companies for Equity-to-Asset. This places Bone Biologics in the top 19% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Bone Biologics' value of 0.89 is 30.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bone Biologics's current Equity-to-Asset of 0.89 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Bone Biologics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bone Biologics's current Equity-to-Asset is 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current Equity-to-Asset of 0.89. The current Equity-to-Asset is 0.89 and 30.9% above the Biotechnology industry median of 0.68. Bone Biologics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Bone Biologics (BBLG), the current Equity-to-Asset is 0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
30GF Score
Get the complete analysis for BBLG
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBLG has been successfully added to your 
